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Introduction {#sec005}
============

Globally, head and neck cancer is the fifth most common cancer and accounts for more than 550,000 new cases each year \[[@pone.0129808.ref001]\]. Consumptions of tobacco (smoking and chewing), alcohol and HPV infection are well-known risk factors toward the development and progression of head and neck squamous cell carcinoma (HNSCC) \[[@pone.0129808.ref002], [@pone.0129808.ref003]\]. In India, HNSCC has profound smoking, betel quid and tobacco chewing profile and comparatively poor survival \[[@pone.0129808.ref004]--[@pone.0129808.ref006]\]. However, HPV positive (+) HNSCC had distinct risk profile and associated with a better survival compared to HPV negative (-) HNSCC \[[@pone.0129808.ref007]\]. Genetic alteration such as mutations and genetic polymorphisms are also play a key mechanism in HNSCC \[[@pone.0129808.ref008]--[@pone.0129808.ref011]\]. In addition, epigenetic modification (variation of gene expression without affecting primary sequence of the DNA) can alter the expression of key tumor-related genes and thus considered as a crucial player to the development of various cancers \[[@pone.0129808.ref012]--[@pone.0129808.ref014]\].

Hypermethylation of CpG islands in the promoter region of genes (those involved in cell cycle regulation, apoptosis, DNA damage repair and detoxification pathway) are associated with cancer progression and development. Thus, aberrant methylation of CpG islands is one of the epigenetic modifications promising immense potential molecular biomarker for prediction and detection of a variety of cancers \[[@pone.0129808.ref015], [@pone.0129808.ref016]\]. CpG island methylator phenotype (CIMP) associated tumors are a distinct group defined by CpG--rich promoter hypermethylation in multiple genes and have a distinct epidemiology and molecular features \[[@pone.0129808.ref017]--[@pone.0129808.ref020]\]. The concept of CIMP was first proposed in colorectal cancer as a molecular marker \[[@pone.0129808.ref021]\], later it was also studied in other tumor types. However, the role of CIMP pathway in the tumorgenesis of HNSCC is still unknown. The major confront in studying and exploring CIMP associated tumors is to define specific methylated loci that should be used as CIMP panel. Aberrant methylation of the normally unmethylated CpG islands is associated with transcriptional inactivation and thus loss of gene expression. Recent investigations conducted on different tumor-related genes also shown differential methylation pattern in HNSCC \[[@pone.0129808.ref022]--[@pone.0129808.ref026]\]. To evaluate and screen CIMP status of cancers, Park etal \[[@pone.0129808.ref027]\] proposed a panel of genes consisting *of p16/CDKN2A*, *MINT1*, *MINT2*, *MINT31* and *MLH1* (referred as classical CIMP panel).The frequencies of hypermethylation in a panel of six genes (*ECAD*, *p16*, *DAPK*, *MGMT*, *RASSF1* and *TIMP3*) were found very high in head and neck cancer \[[@pone.0129808.ref028]\]. In another study, aberrant methylation of *MINT1* and *MINT31* was found to be associated with poor prognosis \[[@pone.0129808.ref029]\]. Earlier studies also reported that *p16* and *DAPK* aberrant methylation was associated with poor prognosis in oral cancers \[[@pone.0129808.ref030], [@pone.0129808.ref031]\]. Therefore, we proposed a CIMP panel of seven genes, including; *DAPK* (death-associated protein kinase), *RASSF1* (Ras association domain family-1), *BRCA1* (breast cancer 1), *MLH1* (mutL homology 1), *p16* (cyclin-dependent kinase inhibitor 2A), *ECAD* (epithelial cadherin), *GSTP1* (glutathione S-transferase pi-1), and three methylated loci such as *MINT1*, *MINT2* and *MINT31* (methylated in tumor 1, 2 and 31 respectively). Recent epigenetic studies on various cancers mainly focused on multigene approach, associations with HPV infection and clinicpathological data and with genetic alterations \[[@pone.0129808.ref032]--[@pone.0129808.ref034]\]. The HPV oncoproteins E6 and E7 are known to be associated with genomic instability by inactivating p53 and Rb tumor suppressor proteins of cell cycle pathway \[[@pone.0129808.ref035]\], apart from this, HPV also modulates aberrant DNA methylation of the host genome \[[@pone.0129808.ref036]\] and cause carcinogenic processes. The past few years, many studies had conducted to explain association of HNSCC with alternation of xenobiotic and DNA repair pathway genes as well as gene-gene and gene-environment interaction \[[@pone.0129808.ref037], [@pone.0129808.ref038]\]. Tahara et al. \[[@pone.0129808.ref039]\] showed genetic factors, related to DNA repair or xenobiotic pathways may have a role in CpG island hypermethylation-related gastric carcinogenesis. However, there were no such studies conducted focusing specific promoter methylation profile in HNSCC with a combination of genetic risk factors related to xenobiotics and DNA repair pathway. Thus, variation in promoter hypermethylation pattern of HNSCC based on habits, genetic alteration and HPV infection remains unclear.

To understand the underlying mechanisms of differences in patterns of tumor-specific hypermethylation, we have analyzed the aberrant promoter methylation profile of HNSCC using seven important tumor-related pathway genes, including *DAPK*, *RASSF1* (apoptosis pathway), *BRCA1*, *MLH1* (DNA repair pathway), *p16* (cell-cycle pathway), *ECAD* (cell-cell adhesion), *GSTP1* (Xenobiotic pathway) and three methylated loci (*MINT1*, *MINT2* and *MINT31*) in the high cancer incidence zone of Northeast India. To the best of our knowledge, we are the first to explore; the correlation of CIMP characteristics with genetic (polymorphisms of *GSTM1*, *GSTT1*, *CYP1A1*, *XRCC1* and *XRCC2* genes) and environmental factors (smoking, betel quid and tobacco chewing) and also with HPV and survival status of HNSCC patients. Furthermore, we performed hierarchical cluster analysis to identify distinct subsets of HNSCC based on the promoter methylation profile.

Materials and Methods {#sec006}
=====================

Collection of HNSCC tissues {#sec007}
---------------------------

In the present study, we examined 116 tissue specimens, including 71 tumor samples of HNSCC and 45 adjacent normal tissues, collected from different hospitals of Northeast India from 2009--2013. Patients gave their written informed consent before collection of the samples. Basic demographic data like age, gender, tobacco (smoking/chewing) consumption, food habits etc. were collected using a standard questionnaire.

Ethics Statement {#sec008}
----------------

Collection, consent form and analysis of tissue samples were approved by Institutional Ethical Committee (IEC), Assam University, Silchar, Assam, India.

DNA extraction {#sec009}
--------------

Genomic DNA was extracted from biopsy samples, surgically excised cancer tissues, and adjacent normal tissues using standard phenol/chloroform extraction protocol and also by Bioline Isolate Genomic DNA minikit (Bioline, UK) following manufacturer's instructions. The extracted DNA was then dissolved in TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA) buffer and stored at -80°C for further analysis \[[@pone.0129808.ref040]\].

HPV detection {#sec010}
-------------

The tissue samples were screened using set of consensus primers My9/My11 for amplifying HPV L1 gene fragments, that can detect high-risk strains of HPV \[[@pone.0129808.ref032]\]. Amplification was carried out on 20 μl reaction mixtures containing 2X Biomix (Bioline, UK), forward and reverse primers, 2 μl sample and nuclease free water. The PCR reaction mixture was subjected to initial denaturation at 94°C for 5 min, followed by 35 cycles at 94°C for 45s, 47°C for 1min and 72°C for 1 min. The final extension was done at 72°C for 10 min. All possible precautions, including negative controls were taken to minimize cross contamination. The PCR products were observed in 2% agarose gel with ethidium bromide staining.

Genetic polymorphisms of carcinogen metabolizing (*GSTM1*, *GSTT1* and *CYP1A1*) and DNA repairs (*XRCC1* and *XRCC2*) genes {#sec011}
----------------------------------------------------------------------------------------------------------------------------

The polymorphisms of *CYP1A1* (T3801C), *XRCC1* (Arg399Gln) and *XRCC2* (Arg188His) genes were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The polymorphic site of *CYP1A1*, *XRCC1* and *XRCC2* was amplified using published forward and reverse primers \[[@pone.0129808.ref037], [@pone.0129808.ref041]\] in 20 μl PCR reactions. Each PCR reaction mixture contains 10--100 ng genomic DNA, 20 pmoles of each primer, 10X reaction buffer, dNTP mix, *Pfu* DNA polymerase, MgCl~2~ and nuclease free water (NFW). The PCR reaction mixture was set with an initial denaturation at 94^°^C for 5 min, followed by 35 cycles of 94^°^C for denaturation for 45s, 62^°^C/ 58^°^C /60^°^C (for *CYP1A1*, *XRCC1* and *XRCC2* respectively) for 45s for primer annealing and extension at 72^°^C for 1 min. The final extension was done at 72^°^C for 10 min. PCR products of *CYP1A1*, *XRCC1* and *XRCC2* were digested separately with the restriction enzyme *Msp1*, *HpaII* and *HphI* enzymes (New England BioLabs, USA) respectively. The digested products were then resolved on 3% agarose gel to assess the size of the PCR--RFLP products \[[@pone.0129808.ref037]\]. Genotyping of the *GSTM1* and *GSTT1* was done by multiplex PCR, using *CYP1A1* gene as an internal control, in a total volume of 10 μl reaction mixture of 2X Biomix (Bioline, UK) and 10 pmole of each of the forward (F) and reverse (R) primers (**[S2 Table](#pone.0129808.s002){ref-type="supplementary-material"}**). The PCR products were electrophoresed in 1.5% agarose gel stained with ethidium bromide.

Promoter hypermethylation analysis and assessment of CIMP-status {#sec012}
----------------------------------------------------------------

Promoter methylation status of tumor-related genes (*RASSF1*, *DAPK*, *ECAD*, *BRCA1*, *MLH1*, *p16* and *GSTP1*) and three methylated loci (*MINT1*, *MINT2*, and *MINT31*) were analyzed using Methylation Specific PCR (MSP) primers (**[S2 Table](#pone.0129808.s002){ref-type="supplementary-material"}**). For MSP assay, DNA samples were subjected to modification using Imprint1 DNA Modification kit (Sigma--Aldrich, St. Louis, MO), following instructions as described by manufacturer's \[[@pone.0129808.ref018]\]. In this procedure, DNA denaturation and bisulfite modification are carried out simultaneously. Bisulfite reacts with single-stranded DNA to deaminate the cytosine (C) and transforms unmethylated cytosine (C) to uracil (U) and leaves 5-methyl cytosine unchanged and thus creates different sequences for methylated and unmethylated DNA. Then we have used two different sets of primers for each gene, one specific set of primers for methylated DNA and the other for unmetyhlated DNA. We also used DNA from peripheral blood lymphocytes of healthy individuals without HPV infection, as negative control, and DNA from peripheral blood lymphocytes treated with SssI methyltranferase was used as positive control (for methylated DNA). All the PCR reaction was performed in gradient thermal cycler (Applied Biosystems, Inc, CA, USA) and the amplified products for methylated and unmethylated DNA were run side by side on agarose gel for comparison. In this study, CIMP panel was classified into three groups: CIMP-high (at least 5 genes/loci methylated out of 10), CIMP-low (less 5/10 genes/loci methylated), and CIMP-negative (0/10 genes/loci methylated). This classification was done on the basis of the criteria previously used for CIMP status in other types of tumor \[[@pone.0129808.ref019], [@pone.0129808.ref042]\]. Methylation index (MI) was also calculated for each case via dividing the number of Methylated genes/loci by the total number of gene/loci under study.

Survival analysis {#sec013}
-----------------

Survival was calculated in months from the beginning of treatment to the month of deathusing Kaplan--Meier survival curves in SPSS software, version 18 (Windows). Deaths due to diseases/complication other than cancer were expelled from the study. The association between different characteristics (HPV, CIMP and cluster) and the event of death was analyzed using Log--rank (Mantel--Cox) tests.

Statistical analysis {#sec014}
--------------------

Statistical analysis was performed using SPSS software version 18 and two-sided *P*-value 0.05 (two-tailed) was considered statistically significant. We used the Wilcoxon rank-sum test to compare promoter methylation levels of HNSCC tumor samples and normal samples, which permit the comparison of two groups of independent samples \[[@pone.0129808.ref043]\]. The significant values were further adjusted for multiple testing by Bonferroni method (*P*-value multiplied by number of comparisons). Also, to strengthen the association between different factors and CIMP in HNSCC risk, *P*-values were calculated after adjusting confounding factors such as age, gender, HPV, smoking, betel-quid and tobacco chewing status as appropriate. Test for linear trend was also carried for multiple ordinal CIMP status. Unsupervised hierarchical clustering was done using JMP 12 software package of SAS, which identify subgroups among HNSCC patients based on promoter methylation frequency.

Results {#sec015}
=======

Characteristics of patients {#sec016}
---------------------------

The clinicopathological data of the 71 studied HNSCC patients are summarized in **[Table 1](#pone.0129808.t001){ref-type="table"},** comprised 51 (71.8%) male and 20 (28.2%) females with an age range of 23--86 years (77.5% belong to the age group 45--86). Of the 71 HNSCC patients; 38 (53.5%) oral cancer (including cheek, base of the tongue, tongue, gingivam, and buccal mucosa) 16 (22.6%) had laryngeal cancer, 8 (11.2%) had pharyngeal cancer and 9 (12.7%) had other cancer types in head and neck region. According to TMN classification, the majority of patients had advanced stage (III/IV) (67.3%) at diagnosis. Among the HNSCC patients, smokers, betel quid chewers and tobacco chewers were 71.8%, 66.2% and 74.6% respectively.

10.1371/journal.pone.0129808.t001

###### Clinicopathological data of HNSCC patients under study.

![](pone.0129808.t001){#pone.0129808.t001g}

  Parameters              Cases (N)   Percentage (%)
  ----------------------- ----------- ----------------
  Gender                              
      Male                51 (71)     71.8
      Female              20 (71)     28.2
  Age                                 
      ≤45                 16 (71)     22.5
      \>45                55 (71)     77.5
  Smoking                             
      Non-smokers         20 (71)     28.2
      Smokers             51 (71)     71.8
  Betel quid chewing                  
      Non-chewers         24 (71)     33.8
      Chewers             47 (71)     66.2
  Tobacco chewing                     
      Non-chewers         18 (71)     25.4
      Chewers             53 (71)     74.6
  Stage                               
      Local (I/II)        17 (52)     32.7
      Advanced (III/IV)   35 (52)     67.3
      NA                  19 (71)     
  Tumor site                          
      Laryngeal           16 (71)     22.6
      Pharyngeal          8 (71)      11.2
      Oral                38 (71)     53.5
  Base of tongue          8 (71)      11.2
      Tongue              4 (71)      5.6
      Cheek               16 (71)     22.6
      Gingivam            4 (71)      5.6
      Buccal mucosa       6 (71)      8.4
  other                   9 (71)      12.7

NA : not available

Frequencies of promoter hypermethylation in tumor samples of HNSCC patients and normal tissues {#sec017}
----------------------------------------------------------------------------------------------

Promoter hypermethylation status of the *p16*, *DAPK*, *GSTP1*, *RASSF1*, *BRCA1*, *ECAD*, *MLH1*, *MINT1*, *MINT2* and *MINT31* genes of 71 HNSCC and 45 normal tissues samples was shown in **[Table 2](#pone.0129808.t002){ref-type="table"}**. Tumor tissues had much higher genes/loci hypermethylation frequency compared to normal tissue samples (32.4% vs. 13.3% for *p16*, 29.6% vs. 11.1% for *DAPK*, 18.3% vs. 8.9% for *BARC1*, 31% vs. 15.6% for *GSTP1*, 32.4% vs. 8.9% for *ECAD*, 50.7% vs. 22.2% for *RASSF1*, 5.6% vs. 2.2% for *MLH1*, 43.7% vs. 13.3% for *MINT1*, 52.1% vs. 11.1% for *MINT2* and 46.5% vs. 17.8% for *MINT31*). However, significantly high level of hypermethylation was observed in *p16*, *DAPK*, *ECAD*, *RASSF1*, *MINT1*, *MINT2* and *MINT31* (*P* = 0.02, 0.02, 0.04, 0.02, 0.01, \<0.01, and 0.01 respectively) in HNSCC tissues compared to normal tissue samples. The methylation index (MI) (ratio of the number of methylated promoters and total number of promoters under study) ranged from 0 to 0.9 of the 71 patients. Out of the 71 HNSCC patients 14 (19.7%) had 0 (zero) MI, 33 (46.5%) had MI of 0.1--0.5 and 24 (33.8%) patients had MI of 0.6--0.9. HNSCC patients with different habits and genetic profiles were found to exhibit differential methylation index (MI). Mean MI of tobacco chewers/smokers was higher than non chewers/smokers. Similarly, patients with *GSTM1* null, *CYP1A1* CC genotype and HPV (+) also shown higher methylation index (**[Fig 1](#pone.0129808.g001){ref-type="fig"}**).

![Methylation index (MI) stratified by genetic and habit related risk factors in HNSCC.\
Each box plot represents differential methylation index (MI) among smokers/chewers and non smokers/chewers or wild genotype vs. variant genotype or HPV (+) vs. HPV (-) HNSCC patients.](pone.0129808.g001){#pone.0129808.g001}

10.1371/journal.pone.0129808.t002

###### Frequency of methylation of follow genes in normal and tumor tissues of HNSCC patients.

![](pone.0129808.t002){#pone.0129808.t002g}

  Genes/loci                   Frequency of methylation (%)               
  ---------------------------- ------------------------------ ----------- ---------------------------------------------
  **Tumor suppressor genes**                                              
  *p16*                                                                   
      Unmethylated             48 (67.6)                      39 (86.7)   
      Methylated               23 (32.4)                      6 (13.3)    0.02
  *DAPK*                                                                  
      Unmethylated             50 (70.4)                      40 (88.9)   
      Methylated               21 (29.6)                      5 (11.1)    0.02
  *BRCA1*                                                                 
      Unmethylated             58 (81.7)                      41 (91.1)   
      Methylated               13 (18.3)                      4 (8.9)     0.16
  *GSTP1*                                                                 
      Unmethylated             49 (69)                        38 (84.4)   
      Methylated               22 (31)                        7 (15.6)    0.06
  *ECAD*                                                                  
      Unmethylated             48 (67.6)                      41 (91.1)   
      Methylated               23 (32.4)                      4 (8.9)     0.04[\*](#t002fn002){ref-type="table-fn"}
  *RASSF1*                                                                
      Unmethylated             35 (49.3)                      35 (77.8)   
      Methylated               36 (50.7)                      10 (22.2)   0.02[\*](#t002fn002){ref-type="table-fn"}
  *MLH1*                                                                  
      Unmethylated             67 (94.4)                      44 (97.8)   
      Methylated               4 (5.6)                        1 (2.2)     0.38
  **Tumor--specific loci**                                                
  *MINT1*                                                                 
      Unmethylated             40 (56.3)                      39 (86.7)   
      Methylated               31 (43.7)                      6 (13.3)    0.01[\*](#t002fn002){ref-type="table-fn"}
  *MINT2*                                                                 
      Unmethylated             34 (47.9)                      40 (88.9)   
      Methylated               37 (52.1)                      5 (11.1)    \<0.01[\*](#t002fn002){ref-type="table-fn"}
  *MINT31*                                                                
      Unmethylated             38 (53.5)                      37 (82.2)   
      Methylated               33 (46.5)                      8 (17.8)    0.01[\*](#t002fn002){ref-type="table-fn"}

Wilcoxon rank-sum test was used to calculate *P*-value

\*Bonferroni correction of significance was applied

Promoter methylation status in HPV positive (+) and HPV negative (-) HNSCC {#sec018}
--------------------------------------------------------------------------

In the study, HPV was detected in 37 out of 71 cases (52.11%) using consensus primers. The correlation between methylation of tumor-related genes and HPV was summarized in **[Table 3](#pone.0129808.t003){ref-type="table"}**. Results shown that promoter methylation of *DAPK*, *RASSF1*, *p16* and *MINT31* were significantly higher in HPV positive (+) HNSCC patients compared to HPV negative (-) patients (*P* = 0.031, 0.013, 0.031 and 0.015) (**[Fig 2B](#pone.0129808.g002){ref-type="fig"}**). A highly significant association was found between HPV positive (+) tumors and CIMP-high group (*P* = 0.028). However, there was no correlation between CIMP-low and HPV (+) HNSCC (*P* = 0.477), when compared with HPV (-) HNSCC tumors.

![(A) Kaplan-Meier survival plots: (i) HPV (+) HNSCC tumors showing better survival compared to HPV (-) tumors. (ii) CIMP-high group of HNSCC tumors showing poorer survival compared to other. (iii) Two epigenetic cluster also showed differential survival with cluster-1 had a poor survival. (B) Frequency of promoter methylation of 10 tumor-related genes/loci in HPV (+) and HPV (-) HNSCC \[\*P\<0.05 (Mantel--Cox Log--rank)\]. (C) Methylation index (MI) in three CIMP-groups of HNSCC tumors.](pone.0129808.g002){#pone.0129808.g002}

10.1371/journal.pone.0129808.t003

###### Frequency of DNA methylation of genes/loci and CIMP status analyzed in HPV (+) and HPV (-) HNSCC.

![](pone.0129808.t003){#pone.0129808.t003g}

  Gene/loci           HPV positive (%)   HPV negative (%)   *P*-value[\*](#t003fn001){ref-type="table-fn"}
  ------------------- ------------------ ------------------ ------------------------------------------------
  *DAPK*                                                    
      Methylated      16 (43.2)          5 (14.7)           
      Unmethylated    21 (56.8)          29 (85.3)          0.031
  *GSTP1*                                                   
      Methylated      16 (43.2)          6 (17.6)           
      Unmethylated    21 (56.8)          28 (82.4)          0.057
  *RASSF1*                                                  
      Methylated      25 (67.6)          11 (32.3)          
      Unmethylated    12 (32.4)          23 (67.7)          0.013
  *BRCA1*                                                   
      Methylated      10 (27.1)          3 (8.9)            
      Unmethylated    27 (72.9)          31 (91.1)          0.066
  *p16*                                                     
      Methylated      17 (45.9)          6 (17.6)           
      Unmethylated    20 (54.1)          28 (82.4)          0.031
  *ECAD*                                                    
      Methylated      16 (43.2)          7 (20.6)           
      Unmethylated    21 (56.8)          27 (79.4)          0.087
  *MINT1*                                                   
      Methylated      19 (51.3)          12 (35.3)          
      Unmethylated    18 (48.7)          22 (64.7)          0.522
  *MINT2*                                                   
      Methylated      20 (54.1)          17 (50)            
      Unmethylated    17 (45.9)          17 (50)            0.782
  *MINT31*                                                  
      Methylated      23 (62.2)          10 (29.4)          
      Unmethylated    14 (37.8)          24 (70.6)          0.015
  *MLH1*                                                    
      Methylated      3 (8.1)            1 (2.9)            
      Unmethylated    34 (91.9)          33 (97.1)          0.327
  CIMP status                                               
      CIMP-negative   3 (8.1)            10 (29.4)          
      CIMP-low        13 (35.1)          17 (50)            0.477
      CIMP-high       21 (56.8)          7 (20.6)           0.028
      *P* ~trend~                                           0.001

\* Chi square test used to calculate *P*-value and further adjusting for age, gender, smoking, betel-quid and tobacco chewing status

*P* \< 0.05 considered as statistically significant

CIMP in HNSCC tumor tissues {#sec019}
---------------------------

In this study, CIMP status was classified as CIMP-high (five or more methylated genes), CIMP-low (less than five methylated genes) and CIMP-negative (no methylated genes). Of the 71 HNSCC samples, 39.4% (28/71) were CIMP-high, 42.3% (30/71) were CIMP-low and 18.3% (13/71) were CIMP-negative.

Correlation between environmental factors and CIMP {#sec020}
--------------------------------------------------

When we analyzed the data on environmental factors such as smoking, betel quid chewing and with CIMP and found smoking and tobacco chewing had strong correlation with CIMP-high (*P* = 0.008 and 0.034 respectively) compared to CIMP-negative. However, betel quid chewing had no significant correlation with CIMP-markers. We also had not found any significant differences between CIMP-low Vs CIMP-negative and CIMP-high Vs CIMP-low in terms of tobacco smoking or chewing (**[Table 4](#pone.0129808.t004){ref-type="table"}**).

10.1371/journal.pone.0129808.t004

###### Correlation between HPV, environmental and genetic characteristics and CIMP-status.

![](pone.0129808.t004){#pone.0129808.t004g}

  Characteristics       CIMP−H (N = 28)   CIMP−L (N = 30)   CIMP−N (N = 13)   *P*-values[\*](#t004fn002){ref-type="table-fn"}           
  --------------------- ----------------- ----------------- ----------------- ------------------------------------------------- ------- -------
  Smoking                                                                                                                               
  Yes                   25 (89.3)         21 (70)           5 (38.5)                                                                    
  No                    3 (10.7)          9 (30)            8 (61.5)          0.008                                             0.044   0.214
  Betel quid chewing                                                                                                                    
  Yes                   20 (71.4)         20 (66.7)         7 (53.8)                                                                    
  No                    9 (28.6)          10 33.3)          6 (46.2)          0.303                                             0.249   0.968
  Tobacco chewing                                                                                                                       
  Yes                   25 (89.3)         22 (73.3)         6 (46.2)                                                                    
  No                    3 (10.7)          8 (26.7)          7 (53.8)          0.034                                             0.207   0.170
  *GSTM1*                                                                                                                               
  Null                  22 (78.6)         14 (46.7)         4 (30.8)                                                                    
  Present               6 (21.4)          16 (53.3)         9 (69.2)          0.023                                             0.731   0.004
  *GSTT1*                                                                                                                               
  Null                  10 (35.7)         15 (50)           4 (30.8)                                                                    
  Present               18 (64.3)         15 (50)           9 (69.2)          0.697                                             0.762   0.281
  *CYP1A1* (T3801C)                                                                                                                     
  Wild (TT)             8 (28.6)          13 (43.3)         8 (61.5)                                                                    
  Heterozygous (TC)     10 (35.7)         11 (36.7)         4 (30.8)          0.997                                             0.931   0.910
  Variant (CC)          10 (35.7)         6 (20)            1 (7.7)           0.180                                             0.456   0.256
  *XRCC1* (Arg399Gln)                                                                                                                   
  Arg/Arg               7 (25)            12 (40)           6 (46.2)                                                                    
  Arg/Gln               14 (50)           11 (36.7)         6 (46.2)          0.108                                             0.624   0.281
  Gln/Gin               7 (25)            7 (23.3)          1 (7.7)           0.056                                             0.230   0.434
  *XRCC2* (Arg188His)                                                                                                                   
  Arg/Arg               14 (50)           22 (73.3)         10 (76.9)                                                                   
  Arg/His               14 (50)           8 (26.7)          3 (23.1)          0.402                                             0.994   0.186

CIMP−H = CIMP-high; CIMP−L = CIMP-low and CIMP−N = CIMP-negative

\* *P*-value was calculated by Chi-square test and further *P*-value was adjusting for age, gender, HPV, smoking, betel-quid and tobacco chewing status (as appropriate)

Correlation between genetic factors and CIMP {#sec021}
--------------------------------------------

We also correlated the genetic alteration data of carcinogen metabolizing (*GSTM1*, *GSTT1* and *CYP1A1*) and DNA repair (*XRCC1* and *XRCC2*) genes with CIMP panel data. The CIMP-high tumors had significantly higher frequency of *GSTM1* null, when compared to the CIMP-low and CIMP-negative tumors (*P* = 0.004 and 0.023 respectively). However, there was no significant correlation between *GSTT1* (null), *CYP1A1* (T3801C), *XRCC1* (Arg/Gln) and *XRCC2* (Arg/His) variant genotypes and different CIMP markers (**[Table 4](#pone.0129808.t004){ref-type="table"}**).

Survival correlates with CIMP and HPV {#sec022}
-------------------------------------

Survival was examined with respect to CIMP markers using Kaplan-Meier survival curves (**[Fig 2A](#pone.0129808.g002){ref-type="fig"}**). Analysis revealed that the overall median survival time of 47 patients out of 71 was 15 months \[95% CI = 10.97--19.03\], and the median survival time in CIMP-high, CIMP-low and CIMP-negative were 11 months \[95% CI = 7.71 to 14.28\], 18 months \[95% CI = 13.73 to 22.26\], and 19 months \[95% CI = 5.14 to 32.85\], respectively (*P* ~*trend*~ = 0.011). Again median survival time for Cluster-1 and Cluster-2 characteristic were 13 and 18 months, respectively (*P* = 0.026) (**[S1 Table](#pone.0129808.s001){ref-type="supplementary-material"}**). The CIMP-high and Cluster-1 were significantly associated with poor survival in patients with HNSCC. Whereas, survival time for the HPV (+) HNSCC patients was better (17 months) than HPV (-) HNSCC patients (13 months) (*P* = 0.041).

Identified tumor clusters and correlation with environmental, genetic and epigenetic characteristics {#sec023}
----------------------------------------------------------------------------------------------------

In the present study, we performed unsupervised hierarchical clustering and identified two classes or sub-groups based on promoter methylation data on tumor samples (**[Fig 3](#pone.0129808.g003){ref-type="fig"}**). We had constructed hierarchical clusters using seven genes/loci, as after adjustment seven gene/loci out of ten found to be significantly hypermethylated. The two identified clusters had distinct environmental, genetic and epigenetic features and are summarized in **[Table 5](#pone.0129808.t005){ref-type="table"}**. The frequency of smoking (86.2%) and tobacco-chewing (89.7%), *GSTM1* null (82.8%) and *CYP1A1* (31.05%), *XRCC1* (27.6%) and *XRCC2* (48.3%) variant genotypes was higher in Cluster-1 compared to Cluster-2. However, only smoking, tobacco chewing and *GSTM1* null genotype had shown statistically significant variation among the clusters (*P* = 0.048, 0.034 and 0.002 respectively). Also, the frequency of HPV positive (+) HNSCC tumors was significantly higher (*P* = 0.009) in Cluster-1 compared to Cluster-2. CIMP-high group (93.1%) is significantly higher in of Cluster-1 (*P*\<0.001) compared to Cluster-2, whereas, Cluster-2 characterized by CIMP-low (66.7%) and CIMP-negative groups (30.9%).

![Unsupervised hierarchical clustering and heatmap was constructed based on promoter methylation data of HNSCC (using significantly methylated seven tumor-related genes/loci).\
The different factors in heatmap were represented by color variation: tobacco consumers, HPV presence and *GSTM1* null, *GSTT1* null (dark red color); tobacco non-consumers and HPV absence *GSTM1* present and *GSTT1* present (light yellow color). For *CYP1A1*, *XRCC1* and *XRCC2* status: wild type (dark red); heterozygous (orange red) and homozygous variant allele (light orange) and for CIMP status: CIMP-high (dark red), CIMP-low (orange red) and CIMP-negative (light color).](pone.0129808.g003){#pone.0129808.g003}

10.1371/journal.pone.0129808.t005

###### Characteristics of the two identified clusters using hierarchical cluster analysis of promoter methylation data.

![](pone.0129808.t005){#pone.0129808.t005g}

  Characteristics         Cluster 1 (N = 29) (%)   Cluster 2 (N = 42) (%)   *P*-value
  ----------------------- ------------------------ ------------------------ -----------
  Smoking                                                                   
      Yes                 25 (86.2)                26 (61.9)                0.048
      No                  4 (13.8)                 16 (38.1)                
  Betel quid chewing                                                        
      Yes                 21 (72.4)                26 (61.9)                0.360
      No                  8 (27.6)                 16 (38.1)                
  Tobacco chewing                                                           
      Yes                 26 (89.7)                27 (64.3)                0.034
      No                  3 (10.3)                 15 (35.7)                
  *GSTM1*                                                                   
      Null                24 (82.8)                16 (38.1)                0.002
      Present             5 (17.2)                 26 (61.9)                
  *GSTT1*                                                                   
      Null                11 (37.9)                18 (42.9)                0.474
      Present             18 (62.1)                24 (57.1)                
  *CYP1A1* (T3801)                                                          
      Wild (TT)           9 (31.05)                20(47.6)                 
      Heterozygous (TC)   11 (37.9)                14 (33.3)                0.997
      Variant (CC)        9 (31.05)                8 (19.1)                 0.371
  *XRCC1* (Arg399Gln)                                                       
      Arg/Arg             8 (27.6)                 17 (40.4)                
      Arg/Gln             13 (44.8)                18 (42.9)                0.428
      Gln/Gin             8 (27.6)                 7 (16.7)                 0.169
  *XRCC2* (Arg188His)                                                       
      Arg/Arg             15 (51.7)                31 (73.8)                
      Arg/His             14 (48.3)                11 (26.2)                0.481
  His/His                 0                        0                        
  HPV status                                                                
      Present             22 (75.9)                15 (35.7)                0.009
      Absent              7 (24.1)                 27 (64.3)                
  CIMP status                                                               
      Positive            27 (93.1)                1 (2.4)                  
      Low                 2 (6.9)                  28 (66.7)                \<0.001
      Negative            0                        13 (30.9)                \<0.001
      *P* ~*trend*~                                                         \<0.001

*P*-values were adjusted for age, gender, smoking, HPV, betel-quid and tobacco chewing as appropriate

Discussion {#sec024}
==========

The development and progression of HNSCC is a multi-step process modulated by genetic, epigenetic and environmental factors \[[@pone.0129808.ref002], [@pone.0129808.ref044], [@pone.0129808.ref045]\]. The major environmental factors such as tobacco smoking and chewing as well as HPV infection may lead to a wide range of genetic and epigenetic proceedings that promote genomic instability and endorse tumor development \[[@pone.0129808.ref003], [@pone.0129808.ref005], [@pone.0129808.ref009]\]. Promoter hypermethylation profile of tumor-related genes was anticipated to be crucial and frequent in different cancers. Many epigenetic events in carcinogenic pathways have been studied recently and revealed the methods for detecting CpG island promoter methylation pattern to stratify high risk groups among different cancers \[[@pone.0129808.ref015], [@pone.0129808.ref017], [@pone.0129808.ref018], [@pone.0129808.ref034]\]. This helps in detection of early onset of cancer, and predicts clinical outcomes. Therefore, it is indispensable to study the methylation status of a panel of representative genes in HNSCC. Here, in this study, we analyzed the aberrant promoter methylation profile of HNSCC using seven important tumor-related pathway genes (*p16*, *DAPK*, *GSTP1*, *ECAD*, *RASSF1*, *MLH1* and *BRCA1*) and three methylated loci (*MINT1*, *MINT2* and *MINT31*) in the high cancer incidence zone of Northeast India. In our study, we also correlate aberrant methylation status of patients with genetic (polymorphisms of *GSTM1*, *GSTT1*, *CYP1A1*, *XRCC1* and *XRCC2*) and environmental factor (smoking, betel quid and tobacco chewing) as well as with survival data.

We found a significantly high level of *p16*, *DAPK*, *ECAD*, *RASSF1*, *MINT1*, *MINT2* and *MINT31* hypermethylation in HNSCC tissues compared to normal tissue samples, reflecting the possible involvement of epigenetic alteration toward the development and progression of HNSCC. Our present investigation had covered a broad group of tumor-related pathway genes, including *p16* (cell-cycle control), *DAPK*, *RASSF1* (apoptosis), *BRCA1*, *MLH1* (DNA repair), *ECAD* (cell-cell adhesion), *GSTP1* (carcinogen metabolism), *MINT1*, *MINT2* and *MINT31* (methylated loci in tumors).

Many previous epigenetic studies elucidated existence of HPV mediated DNA-methylation in HNSCC \[[@pone.0129808.ref046], [@pone.0129808.ref047]\]. Recent study from the Northeast India using a panel of 10 genes, explained the role of HPV and tobacco in the genesis of UADT cancer \[[@pone.0129808.ref032]\]. However, we further analyzed hypermethylation of individual genes/loci separately in HPV (+) and HPV (-) cases. We found promoter methylation of *DAPK*, *p*16, *RASSF1* and *MINT31* was significantly associated with HPV (+) tumors of HNSCC. Therefore, HPV appeared to be a causative agent for alterations of CpG island methylation of tumor-suppressive genes in HNSCC. In general, HPV (+) HNSCC is associated with a more favorable survival \[[@pone.0129808.ref009]\], our study also explored HPV (+) patients of HNSCC had better survival rate compared to HPV (-) patients reflecting a possible role in prognosis.

In many cancer types, especially in colorectal cancer, CpG Island Methylator Phenotype (CIMP) was used to identify clinically and pathologically relevant subsets of tumors. Toyota et al. introduced CpG island methylator phenotype (CIMP) to classify cancer based on the methylation status of a panel of genes \[[@pone.0129808.ref021]\]. In colorectal cancer, CIMP tumors had distinct epidemiologic characteristics, microsatellite instability (MSI) profile BRAF mutations and survival, compared to non-CIMP tumors \[[@pone.0129808.ref048], [@pone.0129808.ref049]\]. CIMPs have been reported for a number of cancers, including upper aerodigestive tract (UADT) \[[@pone.0129808.ref032]\], oral cancer \[[@pone.0129808.ref050]\], and oesophageal squamous cell carcinoma \[[@pone.0129808.ref051]\] and breast cancer \[[@pone.0129808.ref019]\]. However, only single study was there in HNSCC, which explain CIMP in the sub-group of HPV (+) tumor of HNSCC \[[@pone.0129808.ref033]\]. The hypermethylation profile of gene promoters is diverse for each type of cancers and also the detection method and multiple gene selection for CIMP-panel varies among the studies. Based on the hypermethylation pattern of 10 tumor-related genes/loci, we classified HNSCC in three groups: CIMP-high, CIMP-low and CIMP-negative. We observed distinct characteristics of tumor within the CIMP-high and CIMP-negative groups. Frequencies of smoking, tobacco chewing and *GSTM1* null genotypes of patients were significantly higher in CIMP-high groups compared to CIMP-negative. Genetic and environmental characteristics may direct to CIMP characteristics of HNSCC tumors. We also observed an inclination poor survival rate in CIMP-high tumors compared to CIMP-negative group; indicate CIMP-high may be a predictor of a poor prognosis of HNSCC in Northeast Indian population. It is perhaps not unexpected that we have found correlations between the CIMP-high and patient poor outcome, if we compared our data on the CIMP and survival in HNSCC with other previously described cancers \[[@pone.0129808.ref052], [@pone.0129808.ref053]\]. A profound understanding of CIMP could allow designing of better treatment strategies for HNSCC.

Epigenetic clustering of HNSCC patients was done based on DNA methylation profiles in tumor tissue samples. Hierarchical cluster analysis identified two distinct subsets, one subset of HNSCC patients with high frequency of smoking, tobacco chewing habits, *GSTM1* null and *CYP1A1* (CC) variant genotype. The cluster-1 also characterized by HPV (+) cases, and contained CIMP-high group, reflecting a possible correlation between DNA methylation and genetic and environmental factors in HPV associated HNSCC. Thus, epigenetic and along with genetic alteration with a combination of environmental factors may also play a role in a subset of HNSCC. In our previous study, we found strong interaction between carcinogen metabolizing genes (*GSTM1* and *GSTT1*) and environmental factors in HNSCC \[[@pone.0129808.ref002]\]. The interaction of Phase-I (*CYP1A1*) and Phase-II (*GSTM1* & *GSTT1*) tobacco carcinogens metabolizing genes may elucidate the accumulation of the larger amount of toxic substances inside the body that might play the major part during the development of HNSCC. Also, one of our other study explored the interaction between tobacco and DNA repair (*XRCC1* and *XRCC2*) gene polymorphisms and cross talk between these two DNA repair genes towards susceptibility of HNSCC \[[@pone.0129808.ref037]\]. Recent study by Tahara et al. \[[@pone.0129808.ref039]\] found association between *GSTM1* null genotype and increased susceptibility to CpG hypermethylation, however they found reduced susceptibility to CpG hypermethylation of *DAPK* gene with *XRCC1* codon 399 Gln ⁄ Gln genotype and concluded that *GSTM1* null genotype may have a role in CpG hypermethylation related gastric carcinogenesis. We also found significant association between promoter hypermethylation of CpG island and *GSTM1* null genotype in HNSCC. Hierarchical cluster analysis also confirmed this association and thus indicated a possible role of carcinogen metabolizing genes in promoter hypermethylation of tumor-related genes.

In conclusion, promoter hypermethylation of tumor-related genes/loci plays an important role to the development and progression of cancers. Our investigation revealed that epigenetic alteration play as a major mechanism in the carcinogenesis of HNSCC. We also identified distinct subsets of HNSCC based on differential epigenetic, genetic, HPV and environmental characteristics. Furthermore, we could assess the outcome of patients, based on HPV, CIMP and cluster (promoter methylation profiles) characteristic. To the best of our knowledge, this is the first epigenetic, genetic, environmental and prognostic study conducted on HNSCC patients from India. On the whole, this type of study based on promoter methylation analysis in combination with genetic and environmental factors would be helpful in identification of diagnostic and prognostic biomarkers and therapy. Further studies on other population and with larger sample sizes are required for functional validation before the clinical inference can be considered.
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